dermatomyositis: Dermatomyositis (DM) is a type of idiopathic inflammatory myopathy characterized by evocative skin lesions and symmetrical proximal muscle weakness.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
195 |
4. Check minimum number of eventsNone |
195 |
5. Include endpointsNone |
195 |
6. Filter based on genotype QC (FinnGen only) |
177 |
Control definitions (FinnGen only)
- Control exclude
- M13_SYSTCONNECT
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- M33
- Name in latin
- Alia dermatomyositis
Similar endpoints
↥List of similar endpoints to
Other dermatomyositis
based on the number of shared cases.
Similar with more cases:
- Dermatopolymyositis (FG)
- Dermatopolymyositis
- Systemic connective tissue disorders
- Autoimmune diseases related-to ILD
- Autoimmune diseases
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 994 | 672 | 312 |
| Only index persons | 759 | 525 | 234 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.02 | 0.01 |
| Only index persons | 0.02 | 0.02 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 54.13 | 53.64 | 54.89 |
| Only index persons | 51.33 | 51.38 | 51.23 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 177 | 125 | 52 |
| Unadjusted period prevalence (%) | 0.04 | 0.04 | 0.02 |
| Median age at first event (years) | 53.98 | 52.75 | 56.94 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 184
- Matched controls
- 1840
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M33.1
ICD-10 Finland
Other dermatomyositis
+∞
235.8
172
*
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
25.5
115.4
113
108
P01BA02
ATC
hydroxychloroquine; oral
20.2
87.3
83
72
M33.9
ICD-10 Finland
Dermatopolymyositis, unspecified
+∞
86.4
76
*
L04AX01
ATC
azathioprine; systemic
31.8
79.7
56
25
L04AX03
ATC
methotrexate; systemic
16.5
79.5
88
97
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
11.8
53.7
68
87
M33.2
ICD-10 Finland
Polymyositis
+∞
42.3
39
*
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
7.1
36.6
131
473
H02AB06
ATC
prednisolone; systemic
8.8
35.4
152
643
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
10.8
34.6
42
49
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
8.5
31.9
48
73
M35.9
ICD-10 Finland
Systemic involvement of connective tissue, unspecified
314.4
27.5
27
*
H02AB07
ATC
prednisone; oral
6.2
27.0
58
127
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
9.3
26.9
36
47
M05BA04
ATC
alendronic acid; oral
6.9
26.4
48
89
NXL00
NOMESCO Finland
Biopsy of muscle
274.2
24.3
24
*
L04AA06
ATC
mycophenolic acid; systemic
42.6
23.8
29
8
ZX120
NOMESCO Finland
Intravenous
6.1
20.6
41
82
L04AD01
ATC
ciclosporin; systemic
28.7
18.8
25
10
L01BA01
ATC
methotrexate; systemic
14.1
17.1
29
24
M33.0
ICD-10 Finland
Juvenile dermatomyositis
+∞
16.9
16
*
M60.9
ICD-10 Finland
Myositis, unspecified
99.3
16.9
18
*
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
3.6
16.0
86
363
L30.9
ICD-10 Finland
Dermatitis, unspecified
3.7
15.5
66
239
M33
ICD-10 Finland
Dermatopolymyositis
+∞
14.8
14
*
71600
ICD-8 Finland
Polymyositis and dermatomyositis, Dermatomyositis
+∞
14.8
14
*
D07AC01
ATC
betamethasone; topical
3.3
14.0
94
447
7103B
ICD-9 Finland
Diffuse diseases of connective tissue, Dermatomyositis[DERMATOMYOSITIS ADULTORUM]
+∞
13.7
13
*
G72.9
ICD-10 Finland
Myopathy, unspecified
24.7
13.2
18
8
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.2
13.1
117
649
J84.9
ICD-10 Finland
Interstitial pulmonary disease, unspecified
26.6
12.7
17
7
J84.1
ICD-10 Finland
Other interstitial pulmonary diseases with fibrosis
17.5
12.4
19
12
NJ3CG
NOMESCO Finland
Extensive MRI examination of extremities with median high magnet
40.5
12.4
15
*
R4110
NOMESCO Finland
Physiotherapy
3.1
12.3
81
375
UGC12
NOMESCO Finland
Flexible bronchoscopy
5.1
11.9
27
60
L04AA01
ATC
[U] ciclosporin
24.8
11.8
16
7
D07AB08
ATC
desonide; topical
3.9
11.8
40
122
J99.1*M33.9
ICD-10 Finland
Respiratory disorders in dermatopolymyositis
+∞
11.6
11
*
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.9
11.5
39
119
L88
ICPC
Rheumatoid/seropositive arthritis
6.3
11.3
20
35
NJ3BG
NOMESCO Finland
MRI examination of extremities with high intensity magnet
46.3
11.1
13
*
M05BA07
ATC
risedronic acid; oral
8.6
10.8
23
30
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
3.4
10.6
46
165
D07AC13
ATC
mometasone; topical
2.9
10.5
72
335
NGA20
NOMESCO Finland
Exploration of soft tissue knee or lower leg, open
116.4
10.5
11
*
M60.8
ICD-10 Finland
Other myositis
116.4
10.5
11
*
J99.1*M33.2
ICD-10 Finland
Respiratory disorders in polymyositis
+∞
10.5
10
*
M35.0
ICD-10 Finland
Sicca syndrome [Sjögren]
34.7
10.5
13
*
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
4.6
10.4
27
67
M05BX04
ATC
denosumab; parenteral
5.0
9.6
22
49
XX9XE
NOMESCO Finland
Other ultrasound examination
23.2
9.5
13
6
1XC02, ,
NOMESCO Finland
+∞
9.5
9
*
M35.1
ICD-10 Finland
Other overlap syndromes
+∞
9.5
9
*
XQ848
NOMESCO Finland
Dermatological photography
9.1
9.3
19
23
R4120
NOMESCO Finland
Occupational therapy
4.2
9.3
27
73
J84.8
ICD-10 Finland
Other specified interstitial pulmonary diseases
38.8
9.1
11
*
JN4BD
NOMESCO Finland
Extensive body CT
3.6
8.9
33
106
L93.0
ICD-10 Finland
Discoid lupus erythematosus
94.2
8.5
9
*
E0000UV, ,
ATC
2.5
8.5
97
569
QBA99
NOMESCO Finland
Other local destruction of skin of trunk
35.0
8.2
10
*
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.6
7.8
61
297
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
4.5
7.8
20
49
Z3226
NOMESCO Finland
Physiotherapist
2.7
7.7
52
235
GD1ED
NOMESCO Finland
Extensive high resolution CT examination of lungs
9.5
7.7
15
17
M13.9
ICD-10 Finland
Arthritis, unspecified
3.9
7.6
24
69
HA1AA
NOMESCO Finland
X-ray mammography
3.4
7.6
29
95
M32.9
ICD-10 Finland
Systemic lupus erythematosus, unspecified
83.3
7.5
8
*
Z2221
NOMESCO Finland
Medical doctor
2.4
7.5
69
363
R4190
NOMESCO Finland
Nutritional therapy
6.8
7.5
18
29
D07AB02
ATC
hydrocortisone butyrate; topical
2.4
7.4
70
372
XPX04
NOMESCO Finland
Angioscopy
+∞
7.3
7
*
L99
ICPC
Musculoskeletal disease other
8.5
7.3
15
19
M81.4
ICD-10 Finland
Drug-induced osteoporosis
31.4
7.2
9
*
XG410
NOMESCO Finland
Flow-volume spirometry
7.5
7.2
16
23
XG470
NOMESCO Finland
Measurement of diffusion capastity of the lungs
10.7
7.2
13
13
TPH04
NOMESCO Finland
Cathetrisation of vein
2.6
7.1
52
245
TQW80
NOMESCO Finland
Local dermatologic skincare
8.8
7.0
14
17
PJ2AE
NOMESCO Finland
Lymphnode ultrasound examination
41.6
6.8
8
*
ZXE10
NOMESCO Finland
More than one and less than three hours
2.2
6.4
82
489
R91
ICD-10 Finland
Abnormal findings on diagnostic imaging of lung
3.2
6.4
27
94
D02AE01
ATC
carbamide; topical
4.0
6.3
18
48
TGC00
NOMESCO Finland
Bronchial lavation
8.1
6.2
13
17
Z01.8
ICD-10 Finland
Other specified special examinations
2.4
6.2
51
252
C03CA01
ATC
furosemide; systemic
2.2
6.1
67
374
E000001, ,
ATC
2.4
6.1
48
232
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
77
33
39.40
113.16
1.8
1.2
87.00
—
u/ml
—
5
0
52
6
119.65
49.91
1.3
1.0
—
—
—
0
0
54
61
12.11
46.14
2.1
1.4
2.49
3.22
iu/ml
0.22
14
11
46
46
13.00
42.50
1.6
1.1
0.20
0.25
g/l
2.85
46
46
46
48
12.44
41.26
1.6
1.1
1.13
1.25
g/l
1.28
46
48
40
40
12.50
36.72
1.5
1.2
3.58
2.20
u/ml
—
5
5
149
891
4.53
16.15
22.5
10.3
4.07
4.11
e9/l
0.08
143
778
20
6
37.11
16.10
1.3
1.0
—
—
—
0
0
21
13
18.04
13.83
1.3
1.0
—
—
—
0
0
20
12
18.51
13.32
1.3
1.1
—
—
—
0
0
20
12
18.51
13.32
1.3
1.0
—
—
—
0
0
20
13
17.08
12.95
1.3
1.0
—
—
—
0
0
20
13
17.08
12.95
1.3
1.0
—
—
—
0
0
20
14
15.86
12.60
1.3
1.0
—
—
—
0
0
24
51
5.26
11.07
1.4
2.8
0.00
0.00
g/l
-0.00
24
46
21
40
5.80
10.87
1.2
1.4
550.10
0.14
iu/ml
—
6
5
21
41
5.65
10.59
3.8
2.6
—
—
—
0
0
123
799
2.63
8.72
10.7
7.1
1.21
1.21
mmol/l
0.19
113
683
19
45
4.59
7.68
2.8
3.0
4.43
1.57
index
—
7
28
82
462
2.40
7.64
4.6
3.0
0.17
0.52
e6/l
1.97
62
329
33
118
3.19
7.48
1.3
3.4
63.92
66.33
g/l
0.91
33
110
20
51
4.28
7.38
1.1
1.2
—
—
—
0
0
17
43
4.25
6.32
1.8
1.6
—
—
—
0
0
122
857
2.26
6.31
6.3
3.8
0.00
0.00
estimate
-0.00
23
197
124
877
2.27
6.30
6.3
3.8
0.00
0.00
estimate
-0.00
22
191
122
863
2.23
6.11
6.3
3.8
0.00
8.00
estimate
0.50
23
203
16
41
4.18
5.85
1.9
1.6
—
—
—
0
0
50
253
2.34
5.71
2.4
1.8
—
—
—
0
0
10
10
10.49
5.60
2.4
1.3
—
—
—
0
0
38
174
2.49
5.38
2.3
1.8
—
—
—
0
0
52
275
2.24
5.32
3.7
2.8
0.55
0.79
e6/l
0.66
32
139
38
176
2.46
5.24
10.7
8.0
5.49
5.05
kpa
1.40
32
170
38
176
2.46
5.24
10.7
8.0
11.12
12.47
kpa
0.90
32
170
15
35
4.57
4.75
2.0
1.4
—
—
—
0
0
36
170
2.39
4.75
11.1
8.3
2.72
0.75
mmol/l
1.15
29
139
11
18
6.42
4.68
1.9
1.3
—
—
—
0
0
8
9
9.23
4.32
2.6
2.4
—
—
—
0
0
46
254
2.08
4.14
4.2
3.0
3.45
2.75
e6/l
0.21
26
121
52
307
1.97
3.87
4.5
4.0
205.80
258.77
ng/l
0.16
46
238
71
465
1.86
3.87
4.4
3.5
1062.65
1389.58
ng/l
0.54
64
400
11
24
4.80
3.81
1.2
1.4
121.76
160.33
au/ml
—
5
6
12
32
3.94
3.46
2.3
1.4
—
—
—
0
0
11
27
4.26
3.45
1.2
1.4
—
—
—
0
0
9
18
5.20
3.41
1.0
1.3
—
—
—
0
0
35
188
2.06
3.35
2.4
1.7
—
—
—
0
0
6
7
8.81
3.28
1.0
1.1
94.50
87.99
iu/ml
—
6
7
20
85
2.52
3.28
1.4
1.7
—
—
—
0
0
10
24
4.34
3.24
1.2
1.4
—
—
—
0
0
7
11
6.56
3.21
1.0
1.1
—
—
—
0
0
64
426
1.77
3.21
1.5
1.2
1.10
2.01
u/ml
0.68
14
122
76
534
1.72
3.14
8.1
3.0
32.25
29.71
u/l
0.38
71
509
5
5
10.23
2.99
4.0
1.8
58.60
79.66
ug/l
—
5
5
11
32
3.59
2.95
1.8
1.7
—
—
—
0
0
10
27
3.85
2.92
1.0
1.4
—
—
—
0
0
32
179
1.95
2.74
3.3
4.7
2.78
71.25
ug/l
0.89
25
147
9
24
3.89
2.71
1.2
1.3
—
—
—
0
0
9
24
3.89
2.71
1.2
1.3
—
—
—
0
0
8
19
4.35
2.71
2.6
1.3
—
—
—
0
0
10
31
3.35
2.56
1.2
1.5
—
—
—
0
0
10
31
3.35
2.56
1.1
1.1
2.20
5.00
u/ml
—
5
13
7
16
4.50
2.50
1.0
1.3
—
—
—
0
0
7
16
4.50
2.50
1.0
1.1
—
—
—
0
0
9
27
3.45
2.42
3.2
1.3
—
—
—
0
0
11
42
2.72
2.18
1.8
1.3
—
—
—
0
0
5
10
5.10
2.08
1.0
1.1
—
—
—
0
0
134
1494
0.62
2.07
4.8
5.0
5.57
5.93
mmol/l
4.17
129
1370
7
21
3.42
1.98
1.4
1.7
—
—
—
0
0
7
21
3.42
1.98
1.6
3.5
31.66
89.41
u/ml
—
7
21
40
265
1.65
1.96
1.8
1.6
961.85
1267.90
nmol/l
1.70
34
200
5
11
4.64
1.95
1.8
1.2
—
—
—
0
0
64
475
1.53
1.95
5.1
3.2
0.00
0.00
estimate
-0.00
21
149
9
34
2.73
1.89
1.7
1.6
—
—
—
0
0
6
17
3.61
1.85
1.2
2.0
—
—
—
0
0
14
67
2.18
1.81
2.1
2.7
44.86
41.68
u/l
0.27
14
61
82
650
1.47
1.79
6.0
3.7
0.00
0.04
estimate
1.15
20
161
9
36
2.58
1.76
1.1
1.0
—
—
—
0
0
143
1557
0.63
1.70
5.6
5.9
2.84
2.73
mmol/l
0.86
137
1437
36
241
1.61
1.69
2.4
1.9
32.79
29.29
s
0.85
36
235
6
19
3.23
1.67
1.2
1.9
—
—
—
0
0
20
114
1.85
1.64
1.4
1.6
—
—
—
0
0
43
303
1.55
1.63
1.6
1.6
—
—
—
0
0
34
227
1.61
1.62
12.9
7.0
103.97
104.36
mmol/l
0.19
34
227
7
26
2.76
1.59
1.7
2.2
2.64
147.65
u/ml
—
7
26
55
412
1.48
1.57
4.2
2.8
324.75
337.55
umol/l
0.43
48
357
5
15
3.40
1.53
1.2
2.1
—
—
—
0
0
5
15
3.40
1.53
1.2
2.1
—
—
—
0
0
5
15
3.40
1.53
1.2
2.1
—
—
—
0
0
133
1460
0.68
1.49
4.4
4.3
1.28
1.27
mmol/l
0.07
128
1330
44
318
1.50
1.49
1.3
1.3
35.64
34.79
iu/ml
0.02
11
105
142
1538
0.66
1.45
5.2
5.1
4.76
4.69
mmol/l
0.36
136
1419
21
128
1.72
1.40
1.8
2.2
0.12
1.14
e6/l
0.76
21
122
20
122
1.72
1.34
3.0
3.3
52.07
82.18
ng/l
2.45
20
106
142
1531
0.68
1.30
5.2
5.0
1.49
1.52
mmol/l
0.39
135
1407
11
56
2.03
1.25
1.4
1.4
—
—
—
0
0
49
377
1.41
1.20
1.7
1.8
1.13
1.28
mg/l
0.21
38
300
10
50
2.06
1.19
2.2
1.8
—
—
—
0
0
8
39
2.10
1.17
1.1
1.2
—
26.13
—
0
7
12
65
1.91
1.16
1.2
1.5
—
—
—
0
0
20
128
1.63
1.14
2.3
1.4
—
—
—
0
0
39
291
1.43
1.12
1.3
1.3
10.52
18.27
u/ml
0.48
12
102
9
47
1.96
1.04
1.2
1.5
—
—
—
0
0
16
100
1.66
1.00
2.8
3.3
24.99
24.48
mmol/l
0.42
16
100
5
23
2.21
0.98
1.6
1.1
—
—
—
0
0
60
493
1.32
0.96
7.1
3.9
0.00
0.01
estimate
0.50
22
183
9
51
1.80
0.96
4.2
1.8
27.56
24.88
mmol/l
—
9
51
10
55
1.87
0.94
2.6
2.1
—
—
—
0
0
11
65
1.74
0.84
1.8
1.3
—
—
—
0
0
86
758
1.25
0.77
3.7
2.7
—
—
estimate
—
0
0
7
39
1.83
0.73
5.1
2.9
54.43
38.24
u/ml
—
7
39
47
389
1.28
0.71
6.5
3.8
1.02
1.02
kg/l
0.19
37
250
47
394
1.26
0.64
2.3
2.5
—
—
—
0
0
13
89
1.50
0.60
1.0
1.0
—
—
—
0
0
0
22
0.00
0.59
0.0
1.0
—
—
—
0
0
0
23
0.00
0.58
0.0
1.0
—
—
—
0
0
19
248
0.74
0.56
2.8
4.8
18.25
22.41
%
—
10
128
15
108
1.42
0.55
16.7
7.6
27.35
24.95
mmol/l
1.11
15
108
140
1466
0.81
0.53
6.6
6.3
39.66
39.14
mmol/mol
0.29
135
1367
161
1552
1.30
0.51
34.0
15.1
21.08
23.01
mg/l
0.34
147
1262
13
178
0.71
0.51
11.0
6.6
—
—
—
0
0
13
96
1.38
0.43
2.8
2.7
1.18
1.23
%
0.09
13
96
13
96
1.38
0.43
2.8
2.6
0.63
0.63
%
0.02
13
96
8
57
1.42
0.42
1.3
1.6
—
—
—
0
0
18
141
1.31
0.42
2.9
2.2
90.00
65.43
ml/min/173m2
—
7
61
5
33
1.53
0.41
3.0
2.4
6.00
92.58
ug/min
—
5
16
0
16
0.00
0.41
0.0
2.0
—
1.71
—
0
7
0
17
0.00
0.41
0.0
1.0
—
—
—
0
0
0
18
0.00
0.40
0.0
2.1
—
14.81
—
0
9
6
42
1.44
0.36
3.8
1.7
—
—
—
0
0
6
42
1.44
0.36
1.0
1.8
—
—
—
0
0
34
296
1.18
0.33
1.4
1.4
—
—
—
0
0
7
52
1.36
0.31
1.3
1.1
—
—
—
0
0
75
698
1.13
0.30
2.6
2.0
92.95
97.92
pmol/l
0.55
43
349
9
76
1.19
0.25
1.8
1.8
—
—
—
0
0
0
11
0.00
0.21
0.0
2.3
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
11
0.00
0.21
0.0
2.3
—
—
—
0
0
0
11
0.00
0.21
0.0
2.3
—
—
—
0
0
0
11
0.00
0.21
0.0
2.3
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
41.75
—
0
8
0
14
0.00
0.20
0.0
1.1
—
960.97
—
0
14
0
14
0.00
0.20
0.0
1.0
—
519.13
—
0
8
6
51
1.18
0.19
1.2
1.1
—
—
—
0
0
51
476
1.10
0.19
2.1
1.7
20.39
21.13
nmol/l
0.12
45
398
17
195
0.86
0.18
1.6
2.0
1.41
1.49
%
0.26
11
168
18
157
1.16
0.18
6.7
3.8
—
—
—
0
0
17
191
0.88
0.14
2.4
3.0
1.70
0.82
ug/l
0.37
11
125
64
619
1.05
0.09
3.8
3.7
99.91
34.02
ng/l
0.79
54
416
144
1458
0.94
0.08
6.8
5.6
1.73
1.92
mu/l
1.26
137
1347
11
98
1.13
0.08
1.8
1.9
—
—
—
0
0
97
987
0.96
0.06
3.3
3.2
—
—
—
0
0
16
172
0.92
0.06
2.2
1.9
—
—
—
0
0
20
190
1.06
0.04
2.1
2.1
—
—
—
0
0
13
121
1.08
0.04
1.4
1.2
45.39
126.24
u/ml
—
7
48
31
318
0.97
0.02
3.8
5.6
2.34
1.97
ug/l
0.20
25
284
124
1244
0.99
0.00
5.8
4.6
14.79
14.76
pmol/l
0.05
118
1138
69
694
0.99
0.00
2.0
1.9
1.29
1.36
mmol/l
0.37
60
582
51
513
0.99
0.00
3.5
4.0
4.20
8.93
mg/mmol
1.20
29
305
0
6
0.00
0.00
0.0
1.7
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
0.00
0.0
2.9
—
10.15
—
0
8
0
6
0.00
0.00
0.0
1.8
—
—
—
0
0
0
6
0.00
0.00
0.0
1.8
—
—
—
0
0
0
8
0.00
0.00
0.0
2.8
—
44.51
—
0
8
0
8
0.00
0.00
0.0
2.9
—
4.66
—
0
8
0
7
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
15.29
—
0
7
0
7
0.00
-0.00
0.0
2.3
—
51.57
—
0
7
0
9
0.00
-0.00
0.0
2.6
—
—
—
0
0
0
9
0.00
-0.00
0.0
2.6
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
9
0.00
-0.00
0.0
2.6
—
—
—
0
0
9
94
0.96
-0.00
1.3
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
6.2
—
209.20
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint M13_DERMATOMYOTH and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_DERMATOMYOTH | 2.82 [2.11, 3.76] | < 0.001 |
| Birth year | 1.001 [0.99, 1.01] | 0.762 |
During the follow-up period (1.1.1998 — 31.12.2019), 120 out of 411 females with M13_DERMATOMYOTH died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_DERMATOMYOTH | 3.103 [2.28, 4.22] | < 0.001 |
| Birth year | 0.985 [0.98, 0.99] | 0.002 |
During the follow-up period (1.1.1998 — 31.12.2019), 69 out of 201 males with M13_DERMATOMYOTH died.
Mortality risk
Mortality risk for people of age
years, who have M13_DERMATOMYOTH.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.228% | 0.515% |
| 5 | 1.755% | 3.094% |
| 10 | 4.592% | 7.916% |
| 15 | 9.262% | 14.67% |
| 20 | 16.456% | 24.478% |
Relationships between endpoints
↥Index endpoint: M13_DERMATOMYOTH – Other dermatomyositis
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data